A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
← catalyst calendarSponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
659actual
Sites
20
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-23 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | actual | The whole study's end, after follow-up |
| First posted | 2023-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Herpes Zoster
Interventions
- Biological: mRNA-1468
- Biological: Placebo — also filed as Saline
- Biological: Shingrix
Primary outcomes
what the primary-completion date above is the date OFNumber Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions
measured Up to Day 64 (7 days after each injection)
Number of Participants with Unsolicited Adverse Events (AEs)
measured Up to Day 85 (28 days after each injection)
Number of Participants with Serious AEs, AEs Leading to Discontinuation of Study Vaccine or Withdrawal From the Study, and AEs of Special Interest
measured Day 1 to End of Study (up to a maximum of Day 1113)
Number of Participants with Medically Attended AEs
measured Day 1 to Day 393 (12 months after last study injection)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed